Related Experiment Videos
Role of bacteria in experimental colitis
Francisco Guarner1, Juan-R Malagelada
1Digestive System Research Unit, Hospital General Vall d'Hebron, Barcelona 08035, Spain. fguarnera@medynet.com
Best Practice & Research. Clinical Gastroenterology
|September 26, 2003
Summary
Modulating gut flora with probiotics and prebiotics shows promise for managing inflammatory bowel diseases (IBD). Specific probiotic strains, including genetically engineered ones, can prevent colitis in animal models, offering potential therapeutic strategies.
Area of Science:
- Microbiology
- Immunology
- Gastroenterology
Background:
- Gut flora establishment is linked to inflammatory bowel disease (IBD) risk.
- Immune system overactivation against gut bacteria contributes to IBD chronicity.
- Antibiotics and specific gut bacteria influence intestinal inflammation.
Purpose of the Study:
- To explore the role of gut microbiota in inflammatory bowel diseases.
- To investigate the potential of probiotics and prebiotics in managing IBD.
- To identify specific bacterial strains with therapeutic properties for IBD.
Main Methods:
- Review of epidemiological data and animal models of intestinal inflammation.
- Analysis of bacterial species' roles in colonic mucosal barrier dysfunction.
- Evaluation of probiotic strains, including genetically engineered ones, and prebiotics in preventing colitis.
Main Results:
- Certain anaerobic bacteria can invade the colon, inducing inflammation and fibrotic responses.
- Probiotics, including a genetically engineered strain secreting interleukin-10, prevented spontaneous colitis in mice.
- Lactobacilli demonstrated natural anti-inflammatory properties, and prebiotics enhanced their colonization.
Conclusions:
- Modulating gut flora with probiotics and prebiotics may be beneficial for IBD prevention and control.
- Targeted probiotic interventions show potential for managing inflammatory bowel diseases.
- Further research into specific probiotic strains and their mechanisms is warranted.